Want to join the conversation?
For the fourth quarter of 2015, $INTC expects revenue of $14.8Bil, plus or minus $500MM; gross margin of 62%, plus or minus a couple of percentage points; and for full-year 2015, $INTC expects capital spending to be $7.3Bil, plus or minus $500MM.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.